BioStock: SynAct Pharma's CSO comments approved IND and Q3

SynAct Pharma has received IND approval from the FDA, meaning that they can initiate the phase IIa/b RESOLVE study of AP1189 in DMARD-IR patients. They have also just published their report for the third quarter, a busy period with significant progress in the development programmes with AP1189. CSO Thomas Jonassen visited BioStock's studio to talk about the IND approval, patient recruitment in the EXPAND study, financing, and partnering discussions. 

Watch the interview with SynAct Pharma's CSO Thomas Jonassen at biostock.se:

https://www.biostock.se/en/2022/11/synact-pharmas-cso-comments-approved-ind-and-q3

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se